Director Summary Managing Partner and co-founder of Columbus Venture Partners Previous CEO of Highlight Therapeutics and Artax Biopharma Founder of Highlight Therapeutics, Artax Biopharma, Viralgen, Vivet Therapeutics, Polypeptide Therapeutic Solutions, Tyris Therapeutics, and Radioterapia de Protones Bio Damià Tormo has spent the last 20 years working in healthcare and the biotech industry. He is currently…
Scientific Advisor Bio Dr. Christine Brown is the Heritage Provider Network Professor in Immunotherapy at City of Hope Comprehensive Cancer Center. Her research has focused on advancing chimeric antigen receptor (CAR) T cell therapy for the treatment of cancer. As Deputy Director of the T Cell Therapeutics Research Laboratory (TCTRL), Dr. Brown provides scientific oversight…
Mark Leuchtenberger, MBA, is also currently Interim CEO of Brooklyn ImmunoTherapeutics and formerly Chairman, President and CEO of IRX Therapeutics.
Scientific Advisor Bio Assistant member, Center for Cell Engineering, Memorial Sloan Kettering Cancer Center. Member investigator, The Parker Institute for Cancer Immunotherapy. Dr. Klebanoff is cellular immunologist and medical oncologist with 17 years of experience in the pre-clinical and clinical development of T cell-based immunotherapies for the treatment of solid and hematologic cancers. Prior to…
Scientific Advisor Bio Dr. Tasian is a pediatric oncologist and physician-scientist at the Children’s Hospital of Philadelphia and University of Pennsylvania who is interested in development of molecularly-targeted therapeutics for children with high-risk leukemias. Her translational laboratory research program focuses upon testing of kinase inhibitors and chimeric antigen receptor (CAR) T cell immunotherapies in genetic…
Mark Leuchtenberger, MBA, is also currently Interim CEO of Brooklyn ImmunoTherapeutics and formerly Chairman, President and CEO of IRX Therapeutics.
Executive leadership at the Moffitt Cancer Center for Applied Science, Center for Translational Research, Adam Comprehensive Melanoma Center. The McGillicuddy Endowed Chair for Melanoma Research and Treatment.
Chairman of Aleta’s BOD, Founder & board leadership roles at Glycosciences, Galapagos, Celldex, trained at Oxford.
20+ years of senior leadership experience in life science companies. Former CEO of Karus Therapeutics, former head of BD at Ablynx.
Founder/co-founder of 7 biotechs including Avila Therapeutics ($355M Celgene acquisition). Advent Life Sciences venture partner. Former head of Biogen R&D, asst. professor pathology at HMS, PhD Univ. Oxford (Chemistry)